Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Por:
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, Del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L and Gómez-Reino JJ
Publicada:
1 mar 2019
Ahead of Print:
24 oct 2018
Resumen:
The retention rate of a biological drug (percentage of patients remaining on treatment over time) provides an index of a drug's overall effectiveness. The golimumab retention rate as first-line biological therapy was high in clinical trial extensions lasting 5years. Real-world studies also indicate good retention rates but have been of shorter duration. The probability of retention with golimumab treatment was assessed, as any line of anti-tumor necrosis factor-alpha therapy, for up to 5years in patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA) or psoriatic arthritis (PsA), associated factorswere analyzed. A retrospective database analysis of the Spanish registry of patients with rheumatic disorders receiving biological drugs (BIOBADASER) was performed. Among 353 patients, 29.8% had RA, 41.6% SpA and 28.6% PsA. Golimumab was the first biological drug in 40.1% of patients, second in 30.1% and third/later in 29.8%. The overall probability of retention of golimumab at years 1, 2, 3, 4 and 5 was 85.9% (95% confidence interval 81.4-89.5%), 73.7% (67.1-79.1%), 68.5% (60.5-75.1%), 60.6% (50.2-69.5%) and 57.1% (44.9-67.5%), respectively. Retention was similar across indications (p=0.070) but was greater when golimumab was used as the first biological agent compared with later therapy lines (p<0.001). Factors associated with higher retention of golimumab treatment (Cox regression) were use as a first-line biological and concomitant methotrexate treatment; corticosteroid need was associated with lower retention. The long-term probability of golimumab retention was high in this real-world study of patients with rheumatic diseases, especially when used as the first biological drug.
Filiaciones:
Hernandez MV:
Rheumatology Service, Hospital Clinic i Provincial, Barcelona, Spain
Sanchez-Piedra C:
Research Unit, Sociedad Española de Reumatología, Madrid, Spain
Garcia-Magallon B:
Rheumatology Service, Hospital San Jorge, Huesca, Spain
Cuende E:
Rheumatology Service, Hospital Universitario Príncipe de Asturias (Alcalá de Henares), Madrid, Spain
Manero J:
Rheumatology Service, Hospital Miguel Servet, Zaragoza, Spain
Campos-Fernandez C:
Rheumatology Service, Hospital General Universitario Valencia, Valencia, Spain
:
Rheumatology Service, Hospital de Elda, Alicante, Spain
Del Pino-Montes J:
Rheumatology Service, Hospital de Salamanca, Salamanca, Spain
Manrique S:
Rheumatology Service, Hospital Carlos Haya de Málaga, Málaga, Spain
Castro-Villegas MC:
Rheumatology Service, Hospital Reina Sofía (Córdoba), Córdoba, Spain
Ruiz-Montesinos D:
Rheumatology Service, Hospital Virgen de Macarena (Sevilla), Seville, Spain
Sanchez-Alonso F:
Research Unit, Sociedad Española de Reumatología, Madrid, Spain
Diaz-Gonzalez F:
Rheumatology Service, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain
Cea-Calvo L:
Medical Affairs, Department, Merck Sharp and Dohme of Spain, Madrid, Spain
Gómez-Reino JJ:
Rheumatology Department, Hospital Universitario de Santiago de Compostela, C/ Choupana s/n, 15701, Santiago de Compostela, Spain.
hybrid
|